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Background: Chemo-radio therapy (CRT) resistance is a main barrier in treating the triple negative breast cancer
(TNBC). The success of conventional treatment may be ameliorated by elevating the responsiveness of the cancer
cells to CRT. NVP-BEZ235 as a PI3K/AKT/mTOR dual inhibitor has been shown promising results in treating
breast cancer cells. However, potential radiation-sensitizing eﬀect of NVP-BEZ235 in TNBC remained unclear. In
addition, SIRT-1 activation state and environmental cytokine were identiﬁed as being responsible for cancer cells
responses to CRT. Herein, we investigate the role of interleukin 6 (IL-6) as a tumor environmental cytokine and
SIRT1 in the eﬀectiveness of NVP-BEZ235 plus radiotherapy.
Material and methods: TNBC cells were pre-treated with/without IL-6 and were exposed to single and combi-
nation of SRT1720 (SIRT1 activator)/EX-527 (SIRT1 inhibitor) and/or NVP-BEZ235 and/or gamma radiation.
The eﬀect of our treatments on cellular growth was determined by MTT and the cellular death and CSCs per-
centage were determined by Flow cytometry. Senescence detection kit was used to assay the eﬀect of our
treatments on cellular senescence induction.
Results: Activation of SIRT1 via SRT1720 increased the eﬃcacy of CRT in TNBC cells, especially when IL-6 exists
in tumor microenvironment. Additionally, IL-6 pre-treatment followed by exposure to SRT1720 and NVP-
BEZ235 signiﬁcantly increased sensitivity of the cancer stem cells to radiation (p < 0.05).
Conclusion: Our result shows that combination of NVP-BEZ235 and SRT1720 may eﬀectively improve late stage
breast cancer cells therapeutics approach. Activation of SIRT1 and STAT3 in resistance breast cancer cells im-
proves the in-vitro therapeutic eﬃcacy of CRT.
1. Introduction
Breast cancer (BC) is the major causes of cancer-related death
among women. Between the various BC kinds, Triple-negative breast
cancer (TNBC) is known to be extremely metastatic and resistance to
conventional therapies [1]. Therefore, rate of death and metastasis is
higher in women with TNBC [2]. Thus, it is crucial to ﬁnd new stra-
tegies to treat this type of cancer. Several studies have indicated that
activation of phosphatidylinositol 3-kinase (PI3K)/AKt/Mammalian
target of rapamycin (mTOR) signaling via SIRT1 plays a major role in
cancer cells growth and metastasis [3,4]. Activation of PI3K leads to
Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) generation which is
required for the activation of AKT. AKT acts as a proto-oncogene and
mediates mTOR activation, which is common in BC leads to tumor
progression, resistance and survival [3]. In addition, many reports
proposed that PI3k/AKT/mTOR activation mediates cancer progression
and resistance to CRT [5]. It was shown that activation of PI3k/AKT/
mTOR pathway increases cancer stem cells (CSCs) phenotypes [6]. CSCs
are major reason for tumor metastasis, progression and resistance to
combined treatment regimen including CRT [7]. Further evidence
linking SIRT1 expression with PI3k/AKT activation. SIRT1 is a NAD-
dependent histone deacetylase that induces deacetylation and activa-
tion of AKT as well as PI3k. A number of trials have demonstrated that
SIRT1 promotes cancer progression by activating AKT [8,9]. These
trials indicated that elevated activation of PI3k/AKT or expression of
SIRT1 increase resistance to CRT. Activation of SIRT1 [10], similar to
PI3K/AKT, increases tumor metastasis and CSCs phenotype in TNBC
[11]. Based on the ﬁndings of these trials, application of NVP-BEZ235
in combination with SIRT1 activator/inhibitor can reveal promising
outcomes for treatment of patients with TNBC. Despite the PI3k/AKT
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and SIRT1 activation, tumor environmental cytokine has major eﬀects
on the cellular mechanisms of the action. Interleukin 6 (IL-6) is a well-
known tumor environmental cytokine modulates various cellular pro-
cesses, such as apoptosis via activation of SIRT1. Likewise, Maria et al.
have reported that IL-6 directly promote PI3K/AKT activation [12]. In
another study, Seyung et al. reported the IL-6 impress CSCs induction
and resistance to apoptosis in TNBC cells [12]. These observations
suggest that IL-6, SIRT1 and PI3k/AKT/mTOR play a crucial role in
TNBC metastasis and resistance to CRT. Although, NVP-BEZ235 as a
PI3k/AKT/mTOR inhibitor, has shown promising results; but, eﬃcacy
of the drug in combination with radiotherapy and its relation with
SIRT1 activation state remains unclear. In the current study, we in-
vestigated the eﬀect of NVP-BEZ235 as a survival factor inhibitor and
SIRT1 activation/inhibition in the presence of IL-6 plus radiotherapy in
TNBC.
2. Material and methods
2.1. Cell culture
The Human breast cancer cell line, MDA-MB231 was purchased
from the Pasteur Institute (IRAN) and the cells were cultured in com-
plete RPMI 1640, supplemented with 10% heat- inactivated FBS, 1%
pen/strep, in 75ml ﬂasks at 37 °C and 5% CO2. The cells were cultured
with/without 20 ng/ml IL-6 [13] (eBioscience, San Diego, CA, USA) for
2 weeks. Then, the cultures were exposed to 75 nM NVP-BEZ235 (No-
vartis Pharma, Basel, Switzerland) and/or 2 μM SRT1720 (SIRT1
activaor)/EX-527 (SIRT1 inhibitor) (Selleckchem, Houston, TX, USA)
for 24 h (Fig. 1). All mentioned steps were done for gamma irradiation
groups separately, but after 24 h of single and combinatorial drugs
exposure, the ﬂasks were irradiated with 2 Gy of gamma rays. The
cultures were irradiated with 6MV photons under sterile condition at
room temperature. The radiation source was Linac installed in Parsian
Hospital, Shahrekord, Iran, with the following parameters: total dose:
2 Gy, dose rate: 1 Gy/min, medium energy: 6MeV, distance between
center of the source and center of the sample containers: 80 cm.
2.2. Cell viability assay
10,000 numbers of IL-6 treated/untreated cells were seeded in the 4
diﬀerent 96-well plates with 100 μl of culture medium. Afterwards, all
deﬁned treatments were done similarly for 24 h. To investigating the
eﬀects of our treatment with gamma irradiation, 2 of the 96-well plates
(IL-6 treated/untreated) were gamma irradiated. Subsequently, after
performing all treatments, 10 μl of MTT reagent (5mg/ml of PBS) was
added to each well, incubated at 37C for 3 h. For color development,
DMSO was added to solubilize formazan crystals. Absorbance at 590 nm
was measured using ELISA microplatereader.
2.3. Flow cytometry
Cells were trypsinized with 0.05% trypsin 0.25% EDTA and har-
vested. To analyzing the percentage of CSCs, phycoerythrin conjugated
anti CD44 (ebioscience) and FITC conjugated anti CD24 (ebioscience)
Fig. 1. SRT1720 treatment sensitized MDA-MB231 cells to radiation exposure.
MDA-MB231 cells were ﬁrst treated with/without the IL-6 (for 14 d) and then exposed to SRT1720 or EX-527 and/or NVP-BEZ235 (for 24 h) followed by 2 Gy gamma
radiation and then cell viability was assayed. The mean percentage of cell viability ± SD (n= 3) is shown before radiation (A) and after radiation (B). The table
shows the chemical structure of compounds. [Mean ± SD, * p < 0.05, **p < 0.01, ***p < 0.001; compared to the control group (control A= no treatment,
control B= only irradiated culture)]. BEZ; NVP-BEZ235, SRT; SRT1720, EX; EX-527.
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as well as corresponding isotope control were added to the cell sus-
pensions and incubated at 4 °C in dark for 30min. In all cultures the
CD44+/CD24− cells were identiﬁed as a CSC. To investigating cellular
death with ﬂow cytometry, the cells were re-suspended in staining
buﬀer and stained with Annexin V-FITC/PI. All process were performed
at 4 °C. In the last step, the cells were washed and analyzed with a
Partec CyFlow ﬂow cytometer.
2.4. β-Galactosidase staining
Senescence induction was evaluated by a senescence β-
Galactosidase staining kit (abcam). Brieﬂy, cells were washed, ﬁxed and
subsequently exposed to fresh β-Galactosidase (β-Gal) staining solution
at 37 °C overnight. Then the stained senescence cells were evaluated
using an Olympus inverted microscope (Japan).
2.5. Statistical analysis
The data were presented as the mean ± SD for three separated
experiments. All results were compared with related control groups
using the one-way ANOVA with Dunnett’s post hoc test. All analyses
were performed with GraphPad Prism (GraphPad Software, La Jolla,
San Diego, CA). P values< 0.05 or< 0.01 were taken as a statistically
signiﬁcant.
3. Results
3.1. SRT1720 increases triple negative BC cells response to radiotherapy
As expected, MTT assay showed that NVP-BEZ235 decreased the
cell viability of MDA-MB231 cells signiﬁcantly (Fig. 1A; P < 0.05).
Surprisingly, IL-6 pretreatment enhanced the eﬃcacy of NVP-BEZ235
(Fig. 1A; P < 0.001). Inhibition of SIRT-1 with EX-527 non-sig-
niﬁcantly enhanced cell proliferation; however, NVP-BEZ235 or IL-6
abolished the proliferation eﬀect induced by EX-527 (Fig. 1A;
P < 0.05). Interestingly, addition of SRT1720 to the culture medium in
order to increase SIRT-1 activity reduced the population of TNBC cells,
signiﬁcantly (Fig. 1A; P < 0.05); while NVP-BEZ235 modulated the
inhibitory eﬀect of SRT1720 in the combinatorial treatment group.
Combinatorial treatment suggesting that IL-6 increased cytotoxic eﬀect
induced by SRT1720 (Fig. 1A; P < 0.01). Cotreatment with radio-
therapy also reﬂected that SRT1720, sensitized MDA-MB231 cells to
radiotherapy (Fig. 1B; P < 0.001) and IL-6 or NVP-BEZ235 reduced
the eﬀect of SRT1720 on cell sensitization (Fig. 1B; P < 0.05). Al-
though, exposure of the cells to IL-6 enhanced cell sensitization to
radiotherapy after treatment with NVP-BEZ235 and SRT1720 (Fig. 1B;
P < 0.001).
3.2. IL-6 treatment has a major role in scaling down the CSC population
To determine the eﬀects of IL-6 in association with CRT treatment
on CSCs, we cultured MDA-MB231 cells with/without IL-6 for (14 d);
then, the cultures co-treated with NVP-BEZ235 plus SRT1720 or EX-527
and/or radiotherapy. Afterward, the percentage of CD44+/CD24 – cell
populations was investigated by ﬂow cytometry. MDA-MB231 cells
revealed a modest decrease in CSCs population (98%–82%) after PI3 K/
AKT/mTOR pathways were inhibited with NVP-BEZ235 (Fig. 2A;
P < 0.05). Surprisingly, combinatorial treatment of cells with NVP-
BEZ235 and SRT1720 decreased the percentage of CSCs from 98% to
65% (Fig. 2A; P < 0.05). However, similar treatment on IL-6 pre-
treated cells, decreased CSCs as much as NVP-BEZ235 and/or EX-527
treatment groups (Fig. 2A; P < 0.05). We examined the ability of the
irradiation in reduction of CSCs population in TNBC cells. Interestingly,
all combinatorial treatments that contains SRT1720, signiﬁcantly de-
creased CSCs after irradiation (Fig. 2B; P < 0.05). Also, IL-6 pretreat-
ment and SRT1720 with/without NVP-BEZ235 reduced CSCs more
greatly than other groups after radiation (85%–59%). Furthermore,
coculture of cells with IL-6 and EX-527 showed the highest percentage
(95%) of CSCs (Fig. 2B; P < 0.05).
3.3. Activation of SIRT1 reduced senescence induction and increased
radiation induced cellular death
We studied the eﬀect of apoptosis and senescence induction after
our treatments. 24 h after EX527 treatment we recognized an increase
in senescence where the cellular death rate dropped beneath the control
cultures insigniﬁcantly (Fig. 3A & C). Activation of SIRT1 via SRT1720
decreased senescence induction (Fig. 3C) but it increased sensitivity of
TNBC to cellular death through radiotherapy (Fig. 3B; p < 0.01). This
sensitivity increased remarkably when cells were pretreated with IL-6
(Fig. 3B; p < 0.01) and we combined treatment of SRT1720 and NVP-
BEZ235 (Fig. 3B; p < 0.001).
4. Discussion
The role of simultaneous CRT in the BC therapy has earlier been
veriﬁed [14]. The discovery of PI3K/AKT/mToR inhibitor, NVP-
BEZ235 as a novel orally administered drug revealed a new way for
cancer treatment. NVP-BEZ235 is capable to induce cytotoxicity and
cell cycle arrest, based on the cell type and concentration. The function
of this drug may occur via enhancement mitotic inhibitory factors or
inhibit the activation of various kinds of pathways. Combinatorial
therapies have been improved to reduce NVP-BEZ235 side eﬀects and
utilized greater eﬃcacy as well as tolerability in the cancer treatment
[15]. IL-6 is an environmental cytokine that increases metastasis of BC
cells and has a major role in cancer therapies outcomes. The results of
Yin et al. study revealed that eﬀects of IL-6 is extremely depends on
activation of SIRT1 [16].
However, the eﬀectiveness of NVP-BEZ235 with IL-6 pretreated
cells in combination with SIRT1activation/inhibition has remained
unclear yet. Thus, the purpose of the present study was to evaluate the
single and combinatorial eﬀects of NVP-BEZ235 with SIRT1 activation/
inhibition states in metastatic BC cells that pretreated with IL-6. In
addition, the radiotherapy eﬀects on the treated cell were analyzed.
Activation of SIRT1 with SRT1720 induced greater cytotoxic eﬀects in
MDA-MB231 cells and incredibly increased sensitization to radio-
therapy even more than NVP-BEZ235 single treatment. However,
combination of NVP-BEZ235 and SRT1720 reduced cancer stem cells
population signiﬁcantly. Thus, NVP-BEZ235 and SRT1720 combination
provide suitable treatment options when CSCs increased in the tumor
mass. In addition, combinatorial treatment of NVP-BEZ235 and
SRT1720 increased cancer stem cells sensitization to radiotherapy
specially when IL-6 presence in tumor environment. To the best of our
knowledge, the outcomes of the current study proved, for the ﬁrst time,
the synergistic eﬀect of NVP-BEZ235 and SRT1720 for in vitro TNBC
therapy (Fig. 4). Radiotherapy resistance induction via SIRT1 inhibitor
(EX-527) can conﬁrm the additive eﬀect of NVP-BEZ235 and SRT1720
on radiation induced cellular death. Moreover, cells treated with EX-
527 shown no signiﬁcant cytotoxic eﬀect; remarkably proliferation was
detected in TNBC. Similar to our study, Sonnemann et al. demonstrated
that exposure of Ewing’s sarcoma cells to SRT1720 increased the eﬃ-
cacy of chemotherapy [17]. We found that only NVP-BEZ235 enhanced
cellular death signiﬁcantly in non-radiation cultures irrespective of
SIRT1; however, it did not change cellular death signiﬁcantly in ra-
diated groups. In contrast, SRT1720 increased radiation induces cel-
lular death and this cytotoxic eﬀect was augmented upon the addition
of the NVP-BEZ235. The synergistic eﬀects of SRT1720 and NVP-
BEZ235 increased markedly when cells pretreated with IL-6. Thus,
combinatorial treatment of NVP-BEZ235 and SRT1720 could be a
useful therapy for breast cancer when IL-6 represent in tumor micro-
environment. Considerably, IL-6 increase in tumor microenvironment
especially after irradiation [18,19]. It has been shown that the cytotoxic
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Fig. 2. Flow cytometry analysis of CSCs population that displays CD44+CD24- phenotype.
The percentages of CSCs population in all treated cultures (A) before and after (B) radiotherapy. Plots represent mean of 3 independent repeats for each experiment.
[Mean ± SD, * p < 0.05; compared to the control group – (control A=no treatment, control B= only irradiated culture)]. BEZ; NVP-BEZ235, SRT; SRT1720, EX;
EX-527.
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eﬀects of SIRT1720 can be mediated through activation of pATM [20].
Furthermore, IL-6 enhance transcription and phosphorylation of ATM
[20]. Storozhuk et al. have shown that activation of ATM and inhibition
of AKT/mTOR via metformin increases radiation eﬃcacy in none small
cell lung cancer [21]. Thus, we hypothesized that vigorous activation of
ATM through SRT1720 and IL-6 administration is essential for eﬃcient
CRT. Therefore, administration of SRT1720 enhanced cytotoxicity ef-
fects of CRT in comparison with single treatment for BC cells, as
Fig. 2. (continued)
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indicated by the existing cytotoxicity assays. Furthermore, we found
that EX-527 enhanced premature senescence and resistance to radio-
therapy in TNBC cells. Indeed, activation of SIRT1through SRT1720
reduces cellular senescence induction and increases sensitivity of TNBC
cells to NVP-BEZ235 and radiotherapy, especially when IL-6 exists in
the tumor microenvironment. On the other hand, Yao et al. [22] re-
ported that SIRT1 reduced senescence induction through FOXO3a ac-
tivation. IL-6 is a another factor that can activate FOXO3a activation
Fig. 3. Flow cytometry analysis of cellular death.
The percentages of cellular death in all treated cultures (A) before and (B) after radiotherapy. Plots represent mean of 3 independent repeats for each experiment. (C)
β-Galactosidase Staining was used for senescence detection. [Mean ± SD, * p < 0.05, **p < 0.01, ***p < 0.001; compared to the control group (control A= no
treatment, control B= only irradiated culture)]. BEZ; NVP-BEZ235, SRT; SRT1720, EX; EX-527.
Fig. 4. SRT1720 increase the eﬃcacy of NVP-BEZ235 in the presence of IL-6.
SRT1720 increase the cytotoxic eﬀect of NVP-BEZ235 in the presence of IL-6 and sensitized cancer cells to radiation. SRT1720 can decrease the CSCs population and
senescence cells.
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[23]. Moreover, Shiota et al. showed that expression of FOXO3a in-
creases sensitivity of cancer cells to chemotherapy [24]. Therefore, it is
possible to assume that IL-6 and SRT1720 increase sensitivity of cancer
cells to CRT via FOXO3a activation.
NVP-BEZ235 is in phase I/II clinical trials for diﬀerent kinds of
cancers [25]. To improve NVP-BEZ235 eﬀectiveness, we investigated
the eﬀect of this drug in various situations of tumor cells. Tumor micro
environmental and status of the tumor cells have main role in cancer
cells fate. Actually, activation of many signaling pathway may increase
resistance of cancer cells to CRT. To overcome these diﬃculties and to
develop the eﬃcacy of CRT, cellular signaling may be adjusted with
special kinds of the drugs. In our current study, we extended the ef-
fectiveness of NVP-BEZ235 by activating of SIRT1 via SRT1720. Al-
though, recent literature suggest that IL-6 is a tumor promoting factors
but our study demonstrated that IL-6 can increase synergistic eﬀect of
NVP-BEZ235 and SRT1720. The diﬀerence between the studies could
be because of the discrepancy between the cell lines or duration of IL-6
treatment. Thus, chronic presence of IL-6 in tumor microenvironment,
especially at the later stage of BC, combinatorial treatment of NVP-
BEZ235 and SRT1720 could be a useful choice.
5. Conclusion
The results of this study suggest that NVP-BEZ235 in combination
with IL-6 and SRT1720 acts as a chemo/radio-sensitizer and reduces
tumor resistance to CRT by modulating the CSCs ratio and increasing
cellular death in response to a low dose of radiotherapy. Furthermore,
activation of SIRT1 (by SRT1720) and STAT3 via IL-6 increase eﬃcacy
of NVP-BEZ235 in TNBC cells, which are highly metastatic and ag-
gressive. This study demonstrates a novel combinatorial treatment
strategy that by future in vivo study could be implemented in the late
stage- and metastatic tumors of animal models and clinical trials, for
the eﬃcient treatment of CRT resistant breast cancers.
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